Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AQST NASDAQ:CMPX OTCMKTS:TBUFF NASDAQ:TECX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAQSTAquestive Therapeutics$3.82-0.5%$3.57$2.12▼$5.80$379.43M1.991.09 million shs941,366 shsCMPXCompass Therapeutics$2.95-0.7%$2.64$0.87▼$4.08$407.93M1.49713,431 shs815,258 shsTBUFFTribute Pharmaceuticals Canada$0.00$0.50▼$1.86$105.76MN/A71,826 shs50,100 shsTECXTectonic Therapeutic$20.73-6.6%$21.75$13.70▼$61.07$387.09M3.27199,477 shs388,883 shsTen Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAQSTAquestive Therapeutics-0.52%-7.95%+3.80%+27.33%-0.52%CMPXCompass Therapeutics-0.67%-7.23%+12.60%+56.08%+186.41%TBUFFTribute Pharmaceuticals Canada0.00%0.00%0.00%0.00%0.00%TECXTectonic Therapeutic-6.58%-7.12%-1.71%-4.69%+15.68%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAQSTAquestive Therapeutics1.715 of 5 stars3.53.00.00.01.90.00.0CMPXCompass Therapeutics2.3699 of 5 stars3.61.00.00.01.15.00.0TBUFFTribute Pharmaceuticals CanadaN/AN/AN/AN/AN/AN/AN/AN/ATECXTectonic Therapeutic2.8968 of 5 stars3.61.00.00.03.33.30.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAQSTAquestive Therapeutics 3.00Buy$10.14165.52% UpsideCMPXCompass Therapeutics 3.10Buy$12.67329.38% UpsideTBUFFTribute Pharmaceuticals Canada 0.00N/AN/AN/ATECXTectonic Therapeutic 3.17Buy$80.33287.52% UpsideCurrent Analyst Ratings BreakdownLatest TBUFF, TECX, CMPX, and AQST Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/21/2025TECXTectonic TherapeuticTruist FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$64.007/1/2025CMPXCompass TherapeuticsRaymond James FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeOutperform$9.006/17/2025AQSTAquestive TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$10.006/11/2025TECXTectonic TherapeuticRaymond James FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform$76.006/6/2025TECXTectonic TherapeuticLifesci CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform$87.006/5/2025TECXTectonic TherapeuticLifesci CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy6/2/2025AQSTAquestive TherapeuticsOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform$7.005/15/2025AQSTAquestive TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$10.00 ➝ $10.005/15/2025TECXTectonic TherapeuticMizuhoSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$51.00 ➝ $85.005/9/2025CMPXCompass TherapeuticsGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$12.00 ➝ $10.00(Data available from 8/2/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAQSTAquestive Therapeutics$57.56M6.59N/AN/A($0.66) per share-5.79CMPXCompass Therapeutics$850K479.91N/AN/A$0.91 per share3.24TBUFFTribute Pharmaceuticals CanadaN/AN/AN/AN/AN/AN/ATECXTectonic TherapeuticN/AN/AN/AN/A$9.54 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAQSTAquestive Therapeutics-$44.14M-$0.59N/AN/AN/A-100.02%N/A-50.31%8/5/2025 (Estimated)CMPXCompass Therapeutics-$49.38M-$0.41N/AN/AN/AN/A-42.47%-38.31%8/11/2025 (Estimated)TBUFFTribute Pharmaceuticals CanadaN/AN/A0.00N/AN/AN/AN/AN/AN/ATECXTectonic Therapeutic-$57.98M-$7.310.00N/AN/AN/A-30.13%-27.52%8/13/2025 (Estimated)Latest TBUFF, TECX, CMPX, and AQST EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/13/2025Q2 2025TECXTectonic Therapeutic-$0.98N/AN/AN/AN/AN/A8/11/2025Q2 2025CMPXCompass Therapeutics-$0.13N/AN/AN/AN/AN/A8/5/2025Q2 2025AQSTAquestive Therapeutics-$0.18N/AN/AN/A$11.32 millionN/A5/12/2025Q1 2025AQSTAquestive Therapeutics-$0.17-$0.24-$0.07-$0.24$12.23 million$8.72 million5/8/2025Q1 2025CMPXCompass Therapeutics-$0.12-$0.12N/A-$0.12N/AN/A5/8/2025Q1 2025TECXTectonic Therapeutic-$1.10-$0.93+$0.17-$0.93N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAQSTAquestive TherapeuticsN/AN/AN/AN/AN/ACMPXCompass TherapeuticsN/AN/AN/AN/AN/ATBUFFTribute Pharmaceuticals CanadaN/AN/AN/AN/AN/ATECXTectonic TherapeuticN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAQSTAquestive TherapeuticsN/A4.874.48CMPXCompass TherapeuticsN/A8.338.33TBUFFTribute Pharmaceuticals CanadaN/AN/AN/ATECXTectonic TherapeuticN/A22.9222.92Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAQSTAquestive Therapeutics32.45%CMPXCompass Therapeutics68.43%TBUFFTribute Pharmaceuticals CanadaN/ATECXTectonic Therapeutic62.63%Insider OwnershipCompanyInsider OwnershipAQSTAquestive Therapeutics8.35%CMPXCompass Therapeutics29.80%TBUFFTribute Pharmaceuticals CanadaN/ATECXTectonic Therapeutic38.00%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAQSTAquestive Therapeutics16099.33 million91.03 millionOptionableCMPXCompass Therapeutics20138.28 million97.08 millionNot OptionableTBUFFTribute Pharmaceuticals CanadaN/A113.72 millionN/ANot OptionableTECXTectonic Therapeutic12018.67 million11.58 millionN/ATBUFF, TECX, CMPX, and AQST HeadlinesRecent News About These CompaniesY Intercept Hong Kong Ltd Makes New $234,000 Investment in Tectonic Therapeutic, Inc. (NASDAQ:TECX)August 1 at 6:55 AM | marketbeat.comAnalysts Set Tectonic Therapeutic, Inc. (NASDAQ:TECX) Price Target at $80.33July 31 at 2:27 AM | americanbankingnews.comTectonic Therapeutic, Inc. (NASDAQ:TECX) Receives Average Rating of "Buy" from AnalystsJuly 28, 2025 | marketbeat.comWindmill Hill Asset Management Ltd Takes Position in Tectonic Therapeutic, Inc. (NASDAQ:TECX)July 27, 2025 | marketbeat.comWall Street Zen Downgrades Tectonic Therapeutic (NASDAQ:TECX) to SellJuly 26, 2025 | marketbeat.comTectonic Therapeutic (NASDAQ:TECX) Coverage Initiated at Truist FinancialJuly 21, 2025 | marketbeat.comTectonic Therapeutic (NASDAQ:TECX) Upgraded to "Hold" at Wall Street ZenJuly 5, 2025 | marketbeat.comTectonic Therapeutic, Inc. (NASDAQ:TECX) Receives Average Recommendation of "Buy" from BrokeragesJuly 3, 2025 | marketbeat.comTectonic Therapeutic, Inc. Added to Russell 3000® Index Following Annual Reconstitution - NasdaqJuly 1, 2025 | nasdaq.comTectonic Therapeutic joins Russell 3000 indexJune 30, 2025 | msn.comTectonic Therapeutic, Inc. Added to Russell 3000® Index Following Annual ReconstitutionJune 30, 2025 | quiverquant.comQTectonic Therapeutic Joins Russell 3000® IndexJune 30, 2025 | globenewswire.comRaymond James Resumes Coverage of Tectonic Therapeutic (TECX) With an Outperform RatingJune 25, 2025 | msn.comWe Think Tectonic Therapeutic (NASDAQ:TECX) Can Afford To Drive Business GrowthJune 15, 2025 | finance.yahoo.comTectonic Therapeutics (TECX) Gains Outperform Rating from Raymond James | TECX Stock NewsJune 10, 2025 | gurufocus.comLifeSci Capital Initiates Coverage of Tectonic Therapeutic (TECX) with Outperform RecommendationJune 7, 2025 | msn.comTectonic Therapeutic Holds 2025 Annual Stockholders MeetingJune 6, 2025 | tipranks.comTectonic Therapeutic (TECX) Receives Outperform Rating and $87 Price Target | TECX Stock NewsJune 5, 2025 | gurufocus.comTectonic Therapeutic Reports Q1 2025 Financial ResultsMay 30, 2025 | tipranks.comPromising Phase 1b Results and Market Potential Drive Buy Rating for Tectonic Therapeutic’s TX45May 22, 2025 | tipranks.comTectonic Therapeutic Announces Phase 1b Trial ResultsMay 19, 2025 | tipranks.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTBUFF, TECX, CMPX, and AQST Company DescriptionsAquestive Therapeutics NASDAQ:AQST$3.82 -0.02 (-0.52%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$3.84 +0.02 (+0.55%) As of 08/1/2025 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Aquestive Therapeutics, Inc. operates as a pharmaceutical company in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder. Its proprietary product candidates comprise Libervant, a buccal soluble film formulation of diazepam for the treatment of seizures; KYNMOBI, a sublingual film formulation of apomorphine for the treatment of episodic off-periods in Parkinson's disease; and Exservan, an oral soluble film formulation of riluzole for the treatment of amyotrophic lateral sclerosis. The company's proprietary pipeline of complex molecule product includes AQST-108, a sublingual film formulation delivering systemic epinephrine for the treatment of conditions other than anaphylaxis; and Anaphylm, an epinephrine sublingual film for the emergency treatment of allergic reactions, including anaphylaxis. In addition, it develops Adrenaverse, an epinephrine prodrug platform. The company was incorporated in 2004 and is headquartered in Warren, New Jersey.Compass Therapeutics NASDAQ:CMPX$2.95 -0.02 (-0.67%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$2.95 0.00 (0.00%) As of 08/1/2025 07:22 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells. It also develops CTX-8371, a bispecific inhibitor that targets PD-1 and PD-L1 checkpoint inhibitor antibodies. The company was founded in 2014 and is headquartered in Boston, Massachusetts.Tribute Pharmaceuticals Canada OTCMKTS:TBUFFTribute Pharmaceuticals Canada Inc., formerly Stellar Pharmaceuticals Inc., is a Canadian pharmaceutical company with a primary focus on the acquisition, licensing, development and promotion of healthcare products in Canada. The Company targets several therapeutic areas in Canada but has a particular interest in products for the treatment of pain, urology, dermatology and endocrinology/cardiology. It also sells Uracyst and NeoVisc internationally through a number of strategic partnerships. On December 1, 2011, it acquired 100% of Tribute Pharmaceuticals Canada Ltd. and Tribute Pharma Canada Inc. As of December 31, 2011, its portfolio of assets includes nine products: NeoVisc, NeoVisc Single Dose, Uracyst, BladderChek, Bezalip SR, Soriatane, Cambia, Daraprim, and MycoVa. It has licensed BladderChek for the Canadian market from Inverness Medical Innovations North America, Inc. It eveloped Uracyst, a sterile 2 % sodium chondroitin sulfate solution available in a 20 milliliter vial.Tectonic Therapeutic NASDAQ:TECX$20.73 -1.46 (-6.58%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$20.89 +0.16 (+0.77%) As of 08/1/2025 07:16 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Tectonic Therapeutic, Inc. engages in discovery and development of therapeutic proteins & antibodies. The company was founded by Timothy A. Springer and Andrew Kruse in 2019 and is headquartered in Watertown, MA. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 07/28 - 08/01 Alphabet Gains Momentum as Sentiment on Wall Street Improves Amazon's Earnings: What Comes Next and How to Play It Apple Stock: Big Earnings, Small Move—Time to Buy? Tesla Teams With Samsung—Will Other Chipmakers Follow? Will Hims & Hers Fall Along With Novo Nordisk? UPS's 7.5% Dividend: A Blue-Chip Stock on a Once-in-a-Decade Sale Is PG&E an AI Power Play? Why Options Traders Are Betting Big Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
